FIELD: medicine, pharmaceutics.
SUBSTANCE: invention relates to medicine and pharmacology and represents lyophilised medication for treatment of chronic viral hepatitis B or C and AIDS, which contains alpha fetoprotein (AFP) 60-150 mcg, interferon α 3000000-6000000 U and dextran 2-6 mg.
EFFECT: invention ensures improvement of treatment results, reduction of complications and treatment terms.
4 cl, 9 ex
Title | Year | Author | Number |
---|---|---|---|
CYTOKINE-CONTAINING COMPOSITION FOR TREATING VIRAL DISEASES | 2009 |
|
RU2447897C2 |
METHOD OF CHRONIC VIRUS HEPATITIS TREATMENT | 2008 |
|
RU2369403C1 |
METHOD FOR PREPARING PREPARATION DRY ALPHA-FETOPROTEIN | 2005 |
|
RU2283131C1 |
METHOD FOR DETERMINING THE RISK OF HEPATOCELLULAR CARCINOMA IN THE PATIENTS WITH CHRONIC HEPATITIS C | 2019 |
|
RU2723891C1 |
METHOD FOR PREPARING ALPHA-FETOPROTEIN PREPARATION TABLET | 2005 |
|
RU2319479C2 |
METHOD OF TREATING VIRAL HEPATITES | 2012 |
|
RU2489154C1 |
METHOD FOR PRODUCTION OF ALPHA-FETOPROTEIN | 2006 |
|
RU2308286C1 |
METHOD FOR PREDICTION OF FORMATION OF VIROLOGICAL RESPONSE IN PATIENTS WITH CHRONIC HEPATITIS C | 2011 |
|
RU2461834C1 |
METHOD OF PREPARING AN ALPHA-FETOPROTEIN PREPARATION | 1996 |
|
RU2121350C1 |
METHOD FOR PREDICTION OF RISK OF DEVELOPMENT OF HEPATOCELLULAR CARCINOMA IN PATIENTS WITH CHRONIC HEPATITIS C | 2020 |
|
RU2749117C1 |
Authors
Dates
2012-01-20—Published
2010-02-03—Filed